

Supproting Information

Synthesis of Thiazolo[4,5-*d*]pyrimidine derivatives based on Purine via Solid-phase synthesis

Jimin Moon^{a†}, Hyojin Lee^{a†}, Jungtae Kim^{a†}, Shuanghui Hwa^a, GeonHo Yoon^a, Hyeokjin Lee^b, Sugyeong Seo^a, Yoojin Joo^a, Heong-Seop Yim^{b*}, and Taeho Lee^{a*}

a. College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu 41566, Korea.

b. New Drug Development Center, Daegu-Kyeongbuk Medical Innovation Foundation (K-MEDI hub), 80 Cheombok-ro, Dong-gu, Daegu 41061, Republic of Korea.

* = Corresopnding author. E-mail : tlee@knu.ac.kr, yimhs@kmedihub.re.kr

Contents


1.General information.....	2
2. FT-IR Spectra.....	3
3. General synthesis procedures.....	4
4. NMR Spectra of All the compounds.....	23
5. References.....	76

1. Experimental

1.1 General information

All the chemicals were reagent grade and used as purchased. The Merrifield resin (loading capacity 0.98 mmol/g, 100-200 mesh) was purchased from BeadTech (Seoul, Korea). The reactions were monitored by TLC analysis using Merck silica gel 60 F-254 thin layer plates (Merck, Darmstadt, Germany). Flash column chromatography was carried out on Merck silica gel 60 (230–400 mesh). The crude products, which were derived from the solid support, were purified by parallel chromatography using CombiFlash (Isco, Lincoln, NE, USA). The ^1H NMR and ^{13}C NMR spectra were recorded in δ units relative to the deuterated solvent (CDCl_3 , $\text{DMSO}-d_6$, etc.) as an internal reference by the Bruker 500 MHz NMR instrument (Bruker, Billerica, MA, USA). High-performance liquid chromatography (HPLC) system, specifically the Ultimate 3000, coupled with the Q-Exactive Focus quadrupole-Orbitrap MS (Thermo Fisher Scientific, Mass Spectrometry Based Convergence Research Institute, Kyungpook National University, Bremen, Germany). Mass Spectrometry Based Convergence Research Institute, Kyungpook National University The solid-phase synthesis was monitored by FT-IR using JASCO FT-IR 4600


Table S1. Optimization of iodine catalyst mediated oxidative annulation reaction



Entry ^a	Solvent	I ₂ (mol%)	Temp (°C)	Time (h)	Yield (%) ^b
1	DMSO	50	RT ^d	12	NR ^c
2	DMSO	10	RT	3	17
3	DMSO	10	130	1	69
4	DMSO	10	130	2	33
5	DMSO	10	40	12	NR
6	DMSO	10	60	12	Trace
7	DMSO	10	80	4	88
8	DMSO	20	80	4	90
9	DMSO	30	80	4	90
10	DMSO	120	100	0.5	95

a all reaction was performed on **4** (100 mg), benzaldehyde (1.2 eq) and DMSO (3 mL) b isolated yield c No reaction d Room temperature

Table S2. Optimization of thiazolo[4,5-*d*]pyrimidine **9** derivatives for R² substitution




Entry ^a	Base (eq)	Reagent (eq)	Solvent	Temp (°C)	Time (h)	Yield (%) ^b
1	DBU (1.2)	HATU (1.3)	DMF	rt ^c to 70	12	53
2	DBU (1.2)	EDC (1.3)/	DMF	rt	12	NR ^d

		HOBt (1.3)				
3	DBU (1.2)	DCC (1.3)	DMF	rt	12	NR
4	DBU (1.2)	BOP (1.3)	DMF	rt	8	90
5	Et ₃ N (1.2)	BOP (1.3)	DMF	rt	12	Trace


a all reaction was performed 5a (100 mg), butylamine (1.5 eq) and DMF (3 mL) under Ar b isolated yield c room temperature d No reaction

Figure S1. ATR-FTIR spectra of Solid-phase synthesis of thiazolo[4,5-*d*]pyrimidine derivatives **1**




1.2 General procedure

Synthesis of 4-amino-2-(methylthio)thiazole-5-carbonitrile (**3**)¹




To a solution of potassium-methyl cyanocarbonimidodithioate **2** (4 g, 23.5 mmol) in acetone (50 mL) was added bromoacetonitrile (2 mL, 28.5 mmol) at 0 °C under Ar. The reaction mixture was stirred for 0 °C. The reaction mixture was stirred for 1 h at room temperature. After completion of the reaction (monitored by TLC), Et₃N (7 mL, 49.5 mmol) in acetone (20 mL) was dropwised to reaction mixture at 0 °C. The reaction mixture was stirred for 0.5 h at room temperature. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with H₂O and then filtered, washed with H₂O. The solvent of residue was removed and then filtered with H₂O and dried in vacuum oven to give **3** (3.4 g, 85%) as a Ivory solid;

Synthesis of 4-amino-2-(methylthio)thiazole-5-carboxamide (**4**)




To a solution of 4-amino-2-(methylthio)thiazole-5-carbonitrile **3** (2g, 11.6 mmol) in H₂O (10 mL) was added diazobicyclo[5.4.0]undec-7-ene (DBU) (2.1 mL, 14 mmol). The reaction was performed on microwave irradiation (MW) at 100 °C for 0.5 h. The reaction mixture was quenched with 1N HCl for adjust pH 2~3. The solid was filtered with H₂O, and dried in vacuum oven to give **4** (2.1 g, 95%) as yellow solid; ¹H NMR (500 MHz, DMSO-*d*₆) δ 6.94 (s, 2H), 6.87 (s, 2H), 2.63 (s, 3H). ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) δ 167.9, 164.7, 162.1, 92.4, 15.5. HRMS (ESI) *m/z*: [M+H]⁺ Calcd C₅H₈N₃OS₂⁺ 190.0103 Found 190.0103

Synthesis of 4-amino-*N*-(2,4-dimethoxybenzyl)-2-(methylthio)thiazole-5-carboxamide (**8**)




To a solution of potassium cyanocarbonimidodithioate **6** (67.0 mg, 0.34 mmol) in H₂O (0.8 mL) was added solution of 2-chloro-*N*-(2,4-dimethoxybenzyl)acetamide **7** (100.0 mg, 0.41 mmol) dissolved in acetone (4.0 mL) by dropwising at room temperature. After the addition was completed, the reaction mixture was stirred at room temperature for 1 h. The mixture was added LiOH (4.10 mg, 0.35 mmol) at room temperature and reaction mixture was heated under reflux 60 °C for 2 h. After cooling, CH₃I (21.16 μL, 0.34 mmol) in acetone was added dropwise. The mixture was stirred for 1 h at room temperature. The crude product was recrystallized from cold H₂O to give **8** (100.0 mg, 87%) as white solid; ¹H NMR (500 MHz, CDCl₃) δ 7.21 (d, *J* = 8.2 Hz, 1H), 6.48 – 6.41 (m, 2H), 5.95 (s, 2H), 5.58 (t, *J* = 5.3 Hz, 1H), 4.45 (d, *J* = 5.7 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 2.62 (s, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 167.9, 163.4, 161.4, 160.6, 158.7, 130.5, 119.0, 104.1, 98.8, 94.3, 55.5, 55.5, 39.3, 16.2. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₈N₃O₃S₂⁺ 340.0784 Found 340.0785

Synthesis of 4-amino-2-(methylthio)thiazole-5-carboxamide (**4**)




To a solution of 4-amino-*N*-(2,4-dimethoxybenzyl)-2-(methylthio)thiazole-5-carboxamide **8** (100.0 mg, 0.29 mmol) in CH_2Cl_2 (4 mL) was added trifluoroacetic acid (TFA) (0.66 mL, 8.7 mmol) at 0 °C. The reaction mixture was stirred for 5 h. After completion of the reaction (monitored by TLC), the reaction solvent was evaporated and quenched with NaHCO_3 solution. The mixture was extracted with CH_2Cl_2 several times. The organic layer was dried over MgSO_4 . The solvent was removed and crude product was recrystallized from hexane:EtOAc to give **4** (43 mg, 81%) as a yellow solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 6.94 (s, 2H), 6.87 (s, 2H), 2.63 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 167.9, 164.7, 162.1, 92.4, 15.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd $\text{C}_5\text{H}_8\text{N}_3\text{OS}_2^+$ 190.0103 Found 190.0103

Synthesis of 2-(methylthio)-5-phenylthiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5a**)




To a solution of 4-amino-2-(methylthio)thiazole-5-carboxamide **4** (100 mg, 0.53 mmol) in DMSO (3 mL) was added benzaldehyde (64 μL , 0.63 mmol) and iodine (14 mg, 0.053 mmol) at room temperature under atmosphere air. The reaction mixture was stirred at 80 °C for 8 h. After completion of the reaction (monitored by TLC), quenched with $\text{Na}_2\text{S}_2\text{O}_3$ solution and added H_2O . The solid was filter with H_2O and washed with H_2O several times. The solid dried in vacuum oven to give **5a** (131 mg, 90%) as ivory solid; ^1H NMR (500 MHz, CDCl_3) δ 11.55 (s, 1H), 8.28 – 8.20 (m, 2H), 7.66 – 7.53 (m, 3H), 2.86 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 182.7, 167.0, 160.2, 156.8, 133.7, 129.8, 127.8, 113.6, 16.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_{10}\text{N}_3\text{OS}_2^+$ 276.0260 Found 276.0258

5-(4-Methoxyphenyl)-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5b**)




95% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.83 (s, 1H), 8.20 – 8.12 (m, 2H), 7.13 – 7.07 (m, 2H), 3.85 (s, 3H), 2.82 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 183.3, 165.0, 164.7, 159.6, 156.7, 130.1, 120.5, 115.5, 112.7, 55.9, 16.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{O}_2\text{S}_2^+$ 306.0365 Found 306.0366

2-(Methylthio)-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5c**)




94% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.92 (s, 1H), 8.06 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 2.82 (s, 3H), 2.40 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 183.9, 164.3, 159.4, 157.5, 146.2, 130.9, 128.0, 125.4, 113.4, 21.8, 16.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{OS}_2^+$ 290.0416 Found 290.0414

2-(Methylthio)-5-(4-nitrophenyl)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5d**)




95% yield as a pale brown solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 13.33 (s, 1H), 8.39 (s, 4H), 2.83 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 183.3, 167.5, 160.3, 154.1, 150.5, 136.0, 129.0, 124.8, 114.6, 16.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_9\text{N}_4\text{O}_3\text{S}_2^+$ 321.0111 Found 321.0110

5-(3,4-Dimethoxyphenyl)-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5e**)




78% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.86 (s, 1H), 7.85 (dd, J = 8.5, 2.2 Hz, 1H), 7.78 (d, J = 2.2 Hz, 1H), 7.13 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 2.82 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 184.0, 164.0, 159.4, 156.6, 154.4, 149.8, 122.9, 120.1, 112.7, 111.0, 110.1, 56.4, 56.2, 16.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{14}\text{N}_3\text{O}_3\text{S}_2^+$ 336.0471 Found 336.0470

2-(Methylthio)-5-(2,4,6-trimethoxyphenyl)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5f**)




84% yield as a pale yellow solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.73 (s, 1H), 6.33 (s, 2H), 3.85 (s, 3H), 3.73 (s, 6H), 2.80 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 176.3, 167.7, 163.5, 159.6, 158.4, 152.7, 114.6, 104.4, 90.7, 56.0, 55.6, 16.3. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{16}\text{N}_3\text{O}_4\text{S}_2^+$ 366.0577 Found 366.0576

5-(Benzo[d][1,3]dioxol-5-yl)-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5g**)




91% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.80 (s, 1H), 7.78 (dd, J = 8.3, 1.9 Hz, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1H), 6.15 (s, 2H), 2.81 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 183.3, 165.6, 159.7, 156.5, 153.0, 149.3, 123.9, 122.7, 112.9, 109.5, 107.8, 102.7, 16.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{10}\text{N}_3\text{O}_3\text{S}_2^+$ 320.0158 Found 320.0157

5-(4-Fluorophenyl)-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5h**)




98% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 13.03 (s, 1H), 8.27 – 8.18 (m, 2H), 7.41 (t, J = 8.9 Hz, 2H), 2.82 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 183.5, 167.3, 166.5, 165.2, 160.1, 156.0, 130.5, 130.5, 125.8, 125.8, 117.4, 117.2, 113.3, 16.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_9\text{FN}_3\text{OS}_2^+$ 294.0166 Found 294.0164

5-(4-Bromophenyl)-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5i**)




90% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 13.08 (s, 1H), 8.13 – 8.06 (m, 2H), 7.82 – 7.74 (m, 2H), 2.82 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 182.2, 167.8, 160.4, 155.4, 133.0, 129.2, 129.1, 128.6, 113.5, 16.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_9\text{BrN}_3\text{OS}_2^+$ 353.9365 Found 353.9364

5-(4-(Dimethylamino)phenyl)-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5k**)




78% yield as a pale khaki solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.55 (s, 1H), 8.08 (d, J = 9.1 Hz, 2H), 6.79 (d, J = 9.2 Hz, 2H), 3.02 (s, 6H), 2.80 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3 +TFA) δ 183.2, 166.7, 160.1, 153.9, 146.1, 131.5, 130.5, 121.2, 114.3, 46.9, 16.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{15}\text{N}_4\text{OS}_2^+$ 319.0682 Found 319.0681

2-(Methylthio)-5-(thiophen-3-yl)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5l**)




88% yield as a pale grey solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.91 (s, 1H), 8.63 (dd, J = 2.9, 1.2 Hz, 1H), 7.85 (dd, J = 5.1, 1.2 Hz, 1H), 7.73 (dd, J = 5.1, 2.9 Hz, 1H), 2.81 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 175.8, 166.8, 157.7, 151.8, 134.6, 129.6, 127.6, 126.9, 113.9, 15.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{10}\text{H}_8\text{N}_3\text{OS}_3^+$ 281.9824 Found 281.9822

2-(Methylthio)-5-propylthiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5m**)




18% yield as a yellow solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.66 (s, 1H), 2.78 (s, 3H), 2.65 – 2.58 (m, 2H), 1.77 – 1.67 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 177.5, 168.0, 161.2, 160.0, 113.7, 37.2, 21.0, 16.3, 13.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_9\text{H}_{12}\text{N}_3\text{OS}_2^+$ 242.0416 Found 242.0415

5-Cyclohexyl-2-(methylthio)thiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (**5n**)




80% yield as a grey solid; ^1H NMR (500 MHz, CDCl_3) δ 11.42 (s, 1H), 2.83 (s, 3H), 2.70 (tt, J = 11.9, 3.4 Hz, 1H), 2.07 – 1.98 (m, 2H), 1.94 – 1.85 (m, 2H), 1.80 – 1.65 (m, 3H), 1.49 – 1.37 (m, 2H), 1.35 – 1.27 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 177.3, 168.0, 164.7, 159.5, 113.9, 44.3, 30.9, 25.9, 25.6, 16.3. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_{16}\text{N}_3\text{OS}_2^+$ 282.0729 Found 282.0728

Synthesis of *N*-butyl-2-(methylthio)-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine (**9aa**)




To a solution of 2-(methylthio)-5-phenylthiazolo[4,5-*d*]pyrimidin-7(6*H*)-one **5a** (100 mg, 0.36 mmol) in DMF (5 mL) was added DBU (68 μL , 0.43 mmol) and BOP (206 mg, 0.46 mmol) at room temperature. The reaction mixture was stirred for 15 min and added butylamine (54 μL , 0.54 mmol) at room temperature. The reaction mixture was stirred for 6 h. After completion of the reaction (monitored by TLC), the reaction mixture was extracted with EtOAc, washed with NaHCO_3 solution. The combined organic layer was washed with brine. The organic layer was dried over MgSO_4 and filtered. The solvent was removed and the residue purified by silica gel column chromatography (Hx:EtOAc, 2:1) to give **9aa** (107 mg, 90%) as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.59 – 8.51 (m, 2H), 7.49 – 7.41 (m, 3H), 4.88 (s, 1H), 3.68 (dt, J = 7.1, 6.0 Hz, 2H), 2.84 (s, 3H), 1.74 – 1.63 (m, 2H), 1.45 (dq, J = 14.7, 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 174.0, 169.9, 162.6, 157.2, 138.0, 130.3, 128.5, 128.3, 106.4, 41.6, 32.0, 20.2, 16.3, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd $\text{C}_{16}\text{H}_{19}\text{N}_4\text{S}_2^+$ 331.1046 Found 331.1045

Synthesis of *N*-butyl-2-(methylsulfonyl)-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine (**10aa**)




To a solution of *N*-butyl-2-(methylthio)-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine **9aa** (50 mg, 0.15 mmol) in CH_2Cl_2 (4 mL) was added *m*CPBA (87 mg, 0.37 mmol, 77%) at room temperature. The reaction mixture was stirred at 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was extracted with CH_2Cl_2 , washed with NaHCO_3 solution. The combined organic layer was washed with brine. The organic layer was dried over MgSO_4 and filtered. The solvent was removed and the residue purified by silica gel column chromatography (Hx:EtOAc, 2:1) to give **10aa** (45 mg, 82%) as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.66 (t, J = 5.4 Hz, 1H), 8.50 – 8.41 (m, 2H), 7.57 – 7.49 (m, 3H), 3.68 (dd, J = 12.6, 6.9 Hz, 2H), 3.63 (s, 3H), 1.73 – 1.65 (m, 2H), 1.49 – 1.38 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 171.2, 168.1, 162.3, 157.9, 137.4, 130.7, 128.5, 127.9, 110.7, 41.9, 40.3, 30.6, 19.6, 13.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{19}\text{N}_4\text{O}_2\text{S}_2^+$ 363.0944 Found 363.0942

Preparation of 4-amino-*N*-(2,4-dimethoxybenzyl)-2-mercaptothiazole-5-carboxamide resin (**13**)




Merrifield resin (2.5 g, theoretically 2.35 mmol) in DMF (35 mL) was swollen for 0.5 h and added 4-amino-*N*-(2,4-dimethoxybenzyl)-2-mercaptothiazole-5-carboxamide **8** (1.6 g, 3.76 mmol) and Et₃N (0.6 mL, 4.35 mmol) at room temperature. The reaction mixture was shaken at 60 °C for overnight. After completion of the reaction (monitored by ATR-FTIR), the resin was filtered and washed with H₂O, DMF, MeOH and CH₂Cl₂ and dried in a vacuum oven to give **13** (3.48 g, theoretically 0.673 mmol/g) as a yellow resin.

Preparation of 4-amino-2-mercaptothiazole-5-carboxamide (**14**)




To a mixture of 4-amino-*N*-(2,4-dimethoxybenzyl)-2-mercaptothiazole-5-carboxamide resin **14** (1.0 g, theoretically 0.674 mmol) in CH₂Cl₂ (30 mL) was added TFA (2 mL, 25 mmol) under ice bath. The resin was shaken overnight at room temperature. After completion of the reaction (monitored by ATR-FTIR), the resin was filtered and washed with H₂O, DMF, MeOH and CH₂Cl₂ and dried in a vacuum oven to give **14** (0.85 g, theoretically 0.79 mmol/g) as a yellow resin.

Preparation of 2-mercapto-5-phenylthiazolo[4,5-*d*]pyrimidin-7(6*H*)-one resin (**15a**)



To a mixture of 4-amino-2-mercaptothiazole-5-carboxamide **14** (0.85 g, theoretically 0.674 mmol) in DMSO (15 mL) was added benzaldehyde (0.18 mL, 1.7 mmol) and iodine (21 mg, 0.085 mmol) at room temperature. The resin was stirred for overnight at 80 °C under open air. After completion of the reaction (monitored by ATR-FTIR), the resin was filtered and washed with H₂O, DMF, MeOH and CH₂Cl₂ and dried in a vacuum oven to give **15a** (0.88 g, theoretically 0.765 mmol/g) as a yellow resin.


Preparation of 7-(butylamino)-5-phenylthiazolo[4,5-*d*]pyrimidine-2-thiol (**16aa**)



To a mixture of 2-mercapto-5-phenylthiazolo[4,5-*d*]pyrimidin-7(6*H*)-one resin **15a** (0.87 g, theoretically 0.674 mmol) in DMF (20 mL) was added DBU (0.25 mL, 1.7 mmol) and BOP (0.86 mg, 1.95 mmol) at room temperature under Ar. The resin was shaken for 2 h and added butylamine (0.25 mL, 2.55 mmol) at room temperature for x h. After


completion of the reaction (monitored by ATR-FTIR), the resin was filtered and washed with H₂O, DMF, MeOH and CH₂Cl₂ and dried in a vacuum oven to give **16aa** (0.89 g, theoretically 0.75 mmol/g) as a yellow resin.

Preparation of *N*-butyl-2-hydrosulfonyl-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine (**17aa**)




To a mixture of 7-(butylamino)-5-phenylthiazolo[4,5-*d*]pyrimidine-2-thiol **16aa** (0.87 g, theoretically 0.674 mmol) in CH₂Cl₂ (20 mL) was added *m*CPBA (0.62 g, 2.69 mmol) at room temperature under Ar. The resin was shaken for overnight and after completion of the reaction (monitored by ATR-FTIR), the resin was filtered and washed with H₂O, DMF, MeOH and CH₂Cl₂ and dried in a vacuum oven to give **17aa** (0.82 g, theoretically 0.82 mmol/g) as a yellow resin.

Synthesis of *N*²-benzyl-*N*⁷-butyl-5-phenylthiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1aaa**)




The *N*-butyl-2-hydrosulfonyl-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine resin **17aa** (0.4 g, theoretically 0.325 mmol) in CH₂Cl₂ was swollen for 0.5 h and added butylamine (0.10 mL, 0.9 mmol), Et₃N (0.14 mL, 0.9 mmol) at room temperature. The reaction mixture was shaken at room temperature for overnight and then filtered, washed several times with MeOH and CH₂Cl₂. The solvent was removed, and the residue was purified by flash silica gel column chromatography (hexane : EtOAc = 2:1) to give **1aaa** (46 mg, 36%) as a yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 8.54 – 8.46 (m, 2H), 8.05 (s, 1H), 7.48 – 7.37 (m, 3H), 4.59 (s, 1H), 3.66 (dd, *J* = 13.0, 7.0 Hz, 2H), 3.46 (t, *J* = 7.3 Hz, 2H), 1.88 – 1.79 (m, 2H), 1.72 – 1.64 (m, 2H), 1.51 – 1.40 (m, 4H), 0.96 (dt, *J* = 19.9, 7.4 Hz, 6H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.3, 170.0, 161.9, 156.7, 138.7, 129.8, 128.2, 128.1, 99.5, 45.9, 41.5, 32.3, 31.3, 20.2, 20.2, 14.0, 13.8. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₆N₅S⁺ 356.1903 Found 356.1902

*N*²-Benzyl-*N*⁷-butyl-5-phenylthiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1aab**)




19% yield as a white solid; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.34 (s, 1H), 8.37 – 8.28 (m, 2H), 7.73 (s, 1H), 7.48 (dd, *J* = 6.6, 3.6 Hz, 3H), 7.43 – 7.35 (m, 4H), 7.29 (ddd, *J* = 8.6, 3.6, 1.8 Hz, 1H), 4.66 (d, *J* = 4.7 Hz, 2H), 3.55 (dd, *J* = 12.6, 6.9 Hz, 2H), 1.66 – 1.57 (m, 2H), 1.44 – 1.33 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) 170.4, 158.8, 155.8, 138.1, 136.9, 130.3, 128.5, 128.3, 127.6, 127.4, 127.2, 99.9, 47.4, 40.1, 31.2, 19.6, 13.7. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₂H₂₄N₅S⁺ 390.1747 Found 390.1746

*N*⁷-Butyl-5-phenyl-*N*²-(1-phenylethyl)thiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1aac**)




6% yield as a white solid; ¹H NMR (500 MHz, CDCl₃) δ 8.48 – 8.41 (m, 2H), 7.70 (s, 1H), 7.54 – 7.47 (m, 2H), 7.42 – 7.33 (m, 5H), 7.33 – 7.27 (m, 1H), 4.88 (d, *J* = 5.8 Hz, 1H), 4.46 (s, 1H), 3.63 (dd, *J* = 13.0, 7.1 Hz, 2H), 1.79 (d, *J* = 6.8 Hz, 3H), 1.65 (dt, *J* = 12.8, 7.4 Hz, 2H), 1.44 (dq, *J* = 14.7, 7.4 Hz, 2H), 0.97 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 170.3, 169.7, 162.1, 156.8, 142.6, 138.7, 129.9, 129.0, 128.4, 128.2, 127.9, 126.5, 100.2, 56.1, 41.5, 32.4, 23.5, 20.2, 14.0. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₂₆N₅S⁺ 404.1903 Found 404.1903

N-Butyl-2-morpholino-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine (**1aaf**)




38% yield as a white solid; ¹H NMR (500 MHz, CDCl₃) δ 8.55 – 8.50 (m, 2H), 7.47 – 7.40 (m, 3H), 4.58 (s, 1H), 3.87 – 3.79 (m, 4H), 3.76 – 3.70 (m, 4H), 3.67 (td, *J* = 7.1, 5.9 Hz, 2H), 1.73 – 1.64 (m, 2H), 1.46 (dq, *J* = 14.7, 7.4 Hz, 2H), 0.98 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.2, 170.2, 162.2, 156.8, 138.4, 130.0, 128.3, 128.1, 100.3, 66.2, 48.6, 41.6, 32.3, 20.2, 13.9. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₄N₅OS⁺ 370.1696 Found 370.1693

N-Butyl-5-phenyl-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1aag**)




25% yield as a white solid; ¹H NMR (500 MHz, CDCl₃) δ 8.54 (ddd, *J* = 6.8, 4.6, 2.9 Hz, 2H), 7.50 – 7.40 (m, 3H), 7.37 – 7.29 (m, 2H), 7.02 – 6.87 (m, 3H), 4.87 (s, 1H), 3.97 – 3.81 (m, 4H), 3.68 (dd, *J* = 13.0, 7.1 Hz, 2H), 3.44 – 3.28 (m, 4H), 1.77 – 1.62 (m, 2H), 1.48 (dq, *J* = 14.7, 7.4 Hz, 2H), 1.00 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 170.9, 170.3, 162.2, 156.8, 150.8, 138.5, 129.9, 129.4, 128.4, 128.1, 120.9, 117.0, 100.4, 49.2, 48.4, 41.6, 32.3, 20.2, 14.0. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₂₉N₆S⁺ 445.2169 Found 445.2169

N-Butyl-5-phenyl-2-(propylthio)thiazolo[4,5-*d*]pyrimidin-7-amine (**1aai**)




34% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.59 – 8.50 (m, 2H), 7.50 – 7.40 (m, 3H), 4.83 (s, 1H), 3.70 (dd, J = 13.0, 7.1 Hz, 2H), 3.49 – 3.41 (m, 2H), 1.90 – 1.81 (m, 2H), 1.74 – 1.66 (m, 2H), 1.46 (dq, J = 14.7, 7.4 Hz, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 173.4, 170.0, 162.5, 157.1, 138.1, 130.3, 128.5, 128.2, 106.4, 41.6, 35.7, 32.0, 22.6, 20.2, 13.9, 13.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{23}\text{N}_4\text{S}_2^+$ 359.1359 Found 359.1358

*N*²,*N*⁷-Dibenzyl-*N*⁷-methyl-5-phenylthiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1abb**)




16% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.52 (dd, J = 6.7, 3.0 Hz, 2H), 7.44 – 7.27 (m, 13H), 5.95 (s, 1H), 5.03 (s, 2H), 4.72 (s, 2H), 3.32 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 170.3, 159.7, 157.3, 138.4, 138.3, 138.2, 129.8, 128.6, 128.4, 128.2, 127.5, 127.3, 127.2, 127.1, 126.9, 99.1, 52.7, 47.1, 36.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{24}\text{N}_5\text{S}^+$ 438.1747 Found 438.1746

N-Benzyl-*N*-methyl-5-phenyl-2-(pyrrolidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1abd**)




42% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.59 – 8.50 (m, 2H), 7.48 – 7.38 (m, 3H), 7.38 – 7.26 (m, 5H), 5.01 (s, 2H), 3.86 – 3.74 (m, 4H), 3.73 – 3.62 (m, 4H), 3.30 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.4, 168.0, 161.2, 157.9, 138.6, 138.2, 129.8, 128.8, 128.4, 128.0, 127.5, 127.4, 99.7, 53.6, 49.6, 36.4, 25.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{N}_5\text{S}^+$ 402.1747 Found 402.1744

N-Benzyl-*N*-methyl-5-phenyl-2-(piperidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1abe**)




21% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.58 – 8.50 (m, 2H), 7.45 – 7.38 (m, 3H), 7.37 – 7.27 (m, 5H), 5.03 (s, 2H), 3.66 (s, 4H), 3.31 (s, 3H), 1.69 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.4, 171.2, 161.2, 157.8, 138.6, 138.2, 129.8, 128.8, 128.3, 128.0, 127.5, 127.4, 99.6, 53.5, 49.5, 36.3, 25.4, 24.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{26}\text{N}_5\text{S}^+$ 416.1903 Found 416.1900

N-Benzyl-*N*-methyl-2-morpholino-5-phenylthiazolo[4,5-*d*]pyrimidin-7-amine (**1abf**)




49% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.56 – 8.50 (m, 2H), 7.46 – 7.39 (m, 3H), 7.36 – 7.28 (m, 5H), 5.04 (s, 2H), 3.87 – 3.79 (m, 4H), 3.75 – 3.66 (m, 4H), 3.33 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.4, 168.0, 161.2, 157.9, 138.6, 138.2, 129.8, 128.8, 128.4, 128.0, 127.5, 127.4, 99.7, 53.5, 49.6, 36.4, 25.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{N}_5\text{OS}^+$ 418.1696 Found 418.1693

N-Benzyl-*N*-methyl-5-phenyl-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1abg**)



63% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.59 – 8.52 (m, 2H), 7.47 – 7.39 (m, 3H), 7.38 – 7.27 (m, 7H), 6.94 (ddd, $J = 14.7, 8.0, 0.9$ Hz, 3H), 5.03 (s, 2H), 3.89 – 3.83 (m, 4H), 3.33 (s, 3H), 3.32 – 3.27 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.3, 171.1, 161.4, 158.0, 150.9, 138.5, 138.0, 130.0, 129.4, 128.8, 128.4, 128.1, 127.5, 120.9, 117.0, 99.8, 53.6, 49.2, 48.1, 36.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{29}\text{H}_{29}\text{N}_6\text{S}^+$ 493.2169 Found 493.2167


4-(5-Phenyl-2-(piperidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1ace**)



33% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.53 – 8.46 (m, 2H), 7.44 – 7.35 (m, 3H), 3.89 – 3.79 (m,


8H), 3.67 (s, 4H), 1.68 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.9, 170.8, 161.1, 157.6, 138.3, 129.9, 128.3, 128.1, 100.7, 66.8, 49.6, 46.3, 25.4, 24.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{24}\text{N}_5\text{OS}^+$ 382.1696 Found 382.1693

4-(5-Phenyl-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1acg**)




59% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.58 – 8.50 (m, 2H), 7.51 – 7.41 (m, 3H), 7.36 – 7.28 (m, 2H), 7.04 – 6.90 (m, 3H), 4.04 – 3.90 (m, 8H), 3.87 (dd, J = 5.5, 3.6 Hz, 4H), 3.41 – 3.30 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 170.9, 170.7, 160.0, 157.2, 150.5, 138.0, 130.0, 129.0, 128.3, 127.6, 119.6, 116.1, 100.3, 65.9, 47.9, 47.6, 45.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{27}\text{N}_6\text{OS}^+$ 459.1962 Found 459.1959

*N*²,*N*⁷-Dibenzyl-5-(4-methoxyphenyl)-*N*⁷-methylthiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1bbb**)



10% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.02 (s, 1H), 8.32 – 8.24 (m, 2H), 7.39 – 7.32 (m, 6H), 7.27 (ddd, J = 12.2, 8.9, 4.3 Hz, 4H), 7.05 – 6.94 (m, 2H), 4.98 (s, 2H), 4.64 (d, J = 5.5 Hz, 2H), 3.80 (s, 3H), 3.29 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 160.8, 159.6, 157.2, 138.4, 138.2, 130.6, 129.0, 128.6, 128.4, 127.3, 127.2, 127.1, 126.9, 113.5, 98.3, 55.2, 52.7, 47.1, 36.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{27}\text{H}_{26}\text{N}_5\text{OS}^+$ 468.1853 Found 468.1852


N-Benzyl-5-(4-methoxyphenyl)-*N*-methyl-2-(piperidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1bbe**)



33% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.52 – 8.47 (m, 2H), 7.35 – 7.29 (m, 4H), 7.29 – 7.25 (m, 1H), 6.96 – 6.89 (m, 2H), 5.00 (s, 2H), 3.84 (s, 3H), 3.65 (s, 4H), 3.28 (s, 3H), 1.68 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.4, 171.2, 161.2, 161.0, 157.8, 138.2, 131.3, 129.9, 128.7, 127.5, 127.4, 113.3, 98.9, 55.3, 53.5, 49.4,


36.3, 25.4, 24.2. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{25}H_{28}N_5OS^+$ 446.2009 Found 446.2007

N-Benzyl-5-(4-methoxyphenyl)-*N*-methyl-2-morpholinothiazolo[4,5-*d*]pyrimidin-7-amine (**1bbf**)




36% yield as a white solid; 1H NMR (500 MHz, $CDCl_3$) δ 8.52 – 8.46 (m, 2H), 7.36 – 7.25 (m, 5H), 6.95 – 6.89 (m, 2H), 4.99 (s, 2H), 3.83 (s, 3H), 3.81 – 3.76 (m, 4H), 3.70 – 3.64 (m, 4H), 3.28 (s, 3H). $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 171.6, 170.9, 161.3, 161.2, 157.8, 138.0, 131.1, 129.9, 128.7, 127.4, 113.3, 98.9, 66.2, 55.3, 53.5, 48.2, 36.3. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{24}H_{26}N_5O_2S^+$ 448.1802 Found 448.1800

N-Benzyl-5-(4-methoxyphenyl)-7-morpholinothiazolo[4,5-*d*]pyrimidin-2-amine (**1bcb**)



7% yield as a white solid; 1H NMR (500 MHz, $DMSO-d_6$) δ 9.14 (t, J = 5.2 Hz, 1H), 8.35 – 8.21 (m, 2H), 7.43 – 7.33 (m, 4H), 7.32 – 7.27 (m, 1H), 7.07 – 6.90 (m, 2H), 4.66 (d, J = 5.6 Hz, 2H), 3.81 (s, 3H), 3.75 (s, 8H). $^{13}C\{^1H\}$ NMR (126 MHz, $DMSO-d_6$) δ 170.9, 160.8, 159.5, 157.1, 138.3, 130.5, 129.1, 128.5, 127.3, 127.2, 113.5, 99.3, 65.9, 55.2, 45.7, 40.1. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{23}H_{24}N_5O_2S^+$ 434.1646 Found 434.1648


4-(5-(4-Methoxyphenyl)-2-(pyrrolidine-1-yl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1bcd**)



10% yield as a white solid; 1H NMR (500 MHz, $CDCl_3$) δ 8.52 – 8.44 (m, 2H), 6.97 – 6.90 (m, 2H), 3.91 – 3.83 (m, 11H), 3.63 (s, 4H), 2.10 (t, J = 6.6 Hz, 4H). $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 171.7, 17.5, 161.2, 161.0, 157.6, 131.0, 129.8, 113.3, 100.0, 66.8, 55.3, 49.6, 46.2, 25.6. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{20}H_{24}N_5O_2S^+$ 398.1646


Found 398.1647

4-(5-(4-Methoxyphenyl)-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1bcg**)




38% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.51 – 8.44 (m, 4H), 7.33 – 7.27 (m, 4H), 6.98 – 6.90 (m, 10H), 3.92 – 3.86 (m, 15H), 3.84 (dd, J = 7.1, 2.5 Hz, 14H), 3.34 – 3.27 (m, 8H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.5, 170.9, 161.4, 161.2, 157.6, 150.8, 130.9, 129.9, 129.3, 120.9, 117.0, 113.4, 100.1, 66.8, 55.4, 49.2, 48.2, 46.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{29}\text{N}_6\text{O}_2\text{S}^+$ 489.2067 Found 489.2066

N-Butyl-2-(piperidin-1-yl)-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1cae**)




39% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.45 – 8.40 (m, 2H), 7.23 (d, J = 8.0 Hz, 2H), 4.51 (s, 1H), 3.74 – 3.59 (m, 6H), 2.39 (s, 3H), 1.73 – 1.63 (m, 8H), 1.45 (dq, J = 14.6, 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 170.8, 170.6, 162.0, 156.6, 139.8, 135.9, 128.8, 128.3, 99.9, 49.8, 41.5, 32.3, 25.4, 24.2, 21.5, 20.2, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{28}\text{N}_5\text{S}^+$ 382.2060 Found 382.2057

N-Butyl-2-(4-phenylpiperazin-1-yl)-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1cag**)




34% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.44 (d, J = 8.2 Hz, 2H), 7.32 – 7.27 (m, 2H), 7.25 (d, J = 8.0 Hz, 2H), 6.94 (dd, J = 15.1, 7.6 Hz, 3H), 4.62 (t, J = 5.2 Hz, 1H), 3.93 – 3.83 (m, 4H), 3.66 (dd, J = 13.0, 7.1 Hz, 2H), 3.33 – 3.27 (m, 4H), 2.40 (s, 3H), 1.72 – 1.64 (m, 2H), 1.46 (dq, J = 14.7, 7.4 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 170.8, 170.3, 162.2, 156.7, 150.8, 139.9, 135.7, 129.3, 128.9, 128.3, 120.9, 117.0, 100.1, 49.1, 48.3, 41.5, 32.3, 21.5, 20.2, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{31}\text{N}_6\text{S}^+$ 459.2325 Found 459.2323

*N*²,*N*⁷-Dibenzyl-*N*⁷-methyl-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1cbb**)




6% yield as a white solid; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.03 (t, *J* = 5.2 Hz, 1H), 8.22 (d, *J* = 8.2 Hz, 2H), 7.39 – 7.22 (m, 12H), 4.99 (s, 2H), 4.64 (d, *J* = 5.5 Hz, 2H), 3.30 (s, 3H), 2.34 (s, 3H). ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) δ 170.3, 159.7, 157.2, 139.4, 138.4, 138.2, 135.5, 128.8, 128.6, 128.4, 127.5, 127.3, 127.2, 127.1, 126.9, 98.8, 82.7, 47.1, 36.4, 20.9. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₇H₂₆N₅S⁺ 452.1903 Found 452.1902

N-Benzyl-*N*-methyl-2-(piperidin-1-yl)-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1cbe**)




19% yield as a white solid; ¹H NMR (500 MHz, CDCl₃) δ 8.47 – 8.41 (m, 2H), 7.38 – 7.30 (m, 4H), 7.29 – 7.26 (m, 1H), 7.21 (d, *J* = 8.0 Hz, 2H), 5.02 (s, 2H), 3.66 (s, 4H), 3.29 (s, 3H), 2.38 (s, 3H), 1.68 (s, 6H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.4, 171.2, 161.3, 157.8, 139.8, 138.2, 135.9, 128.8, 128.7, 128.3, 127.6, 127.4, 99.3, 53.5, 49.5, 36.3, 25.4, 24.2, 21.5. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₂₈N₅S⁺ 430.2060 Found 430.2061

N-Benzyl-*N*-methyl-2-(4-phenylpiperazin-1-yl)-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1cbg**)




22% yield as a white solid; ¹H NMR (500 MHz, CDCl₃) δ 8.48 – 8.42 (m, 2H), 7.37 – 7.27 (m, 7H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.00 – 6.89 (m, 3H), 5.03 (s, 2H), 3.88 – 3.82 (m, 4H), 3.32 (s, 3H), 3.31 – 3.27 (m, 4H), 2.40 (s, 3H). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.3, 171.1, 161.5, 157.9, 150.9, 140.0, 138.0, 135.7, 129.4, 128.9, 128.8, 128.3, 127.5, 127.5, 120.9, 117.0, 99.5, 53.5, 49.2, 48.1, 36.4, 21.5. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₃₀H₃₁N₆S⁺ 507.2325 Found 507.2326

4-(2-(Piperidin-1-yl)-5-(*p*-tolyl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1cce**)




42% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.39 (d, J = 8.2 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 3.85 (td, J = 6.7, 4.4 Hz, 8H), 3.68 (s, 4H), 2.38 (s, 3H), 1.69 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.8, 170.8, 161.3, 157.5, 140.0, 135.6, 128.8, 128.2, 100.4, 66.9, 49.6, 46.3, 25.4, 24.2, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{26}\text{N}_5\text{OS}^+$ 396.1853 Found 396.1852

4-(2-(4-Phenylpiperazin-1-yl)-5-(p-tolyl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1ccg**)




42% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.41 (d, J = 8.2 Hz, 2H), 7.34 – 7.27 (m, 2H), 7.24 (d, J = 8.0 Hz, 2H), 6.99 – 6.90 (m, 3H), 3.86 (ddd, J = 8.2, 5.2, 3.1 Hz, 12H), 3.34 – 3.27 (m, 4H), 2.40 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.5, 170.9, 161.4, 157.6, 150.8, 140.1, 135.5, 129.3, 128.9, 128.2, 120.9, 117.0, 100.5, 66.8, 49.1, 48.2, 46.2, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{29}\text{N}_6\text{OS}^+$ 473.2118 Found 473.2117

N-Butyl-5-(4-fluorophenyl)-2-(piperidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1hae**)




60% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.56 – 8.48 (m, 2H), 7.13 – 7.03 (m, 2H), 4.51 (t, J = 5.2 Hz, 1H), 3.74 – 3.59 (m, 6H), 1.74 – 1.61 (m, 8H), 1.45 (dq, J = 14.6, 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 170.8, 170.5, 165.2, 163.2, 161.1, 156.6, 134.8, 134.8, 130.4, 130.3, 114.9, 114.8, 100.1, 49.8, 41.5, 32.3, 25.4, 24.2, 20.2, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{25}\text{FN}_5\text{S}^+$ 386.1809 Found 386.1807

N-Butyl-5-(4-fluorophenyl)-2-morpholinethiazolo[4,5-*d*]pyrimidin-7-amine (**1haf**)




28% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.56 – 8.46 (m, 2H), 7.14 – 7.04 (m, 2H), 4.53 (t, J = 5.0 Hz, 1H), 3.82 (dd, J = 6.4, 3.4 Hz, 4H), 3.78 – 3.69 (m, 4H), 3.66 (dt, J = 13.0, 6.5 Hz, 2H), 1.75 – 1.64 (m, 2H), 1.46 (dq, J = 14.7, 7.4 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.3, 170.1, 165.3, 163.3, 161.3, 156.7, 134.6, 134.6, 130.3, 130.3, 115.0, 114.9, 100.2, 66.2, 48.5, 41.5, 32.2, 20.2, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{23}\text{FN}_5\text{OS}^+$ 388.1602 Found 388.1599

N-Butyl-5-(4-fluorophenyl)-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1hag**)




74% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.57 – 8.49 (m, 2H), 7.31 – 7.26 (m, 2H), 7.14 – 7.06 (m, 2H), 6.96 – 6.89 (m, 3H), 4.68 (t, J = 5.4 Hz, 1H), 3.84 (d, J = 4.6 Hz, 4H), 3.63 (dd, J = 13.0, 7.0 Hz, 2H), 3.33 – 3.24 (m, 4H), 1.72 – 1.60 (m, 2H), 1.51 – 1.38 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 170.9, 170.1, 165.2, 163.2, 161.1, 156.6, 150.7, 134.6, 134.6, 130.3, 130.2, 129.3, 120.8, 116.9, 115.0, 114.8, 100.3, 49.0, 48.3, 41.4, 32.2, 20.1, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{28}\text{FN}_6\text{S}^+$ 463.2075 Found 463.2074

*N*⁷-Benzyl-*N*²-butyl-5-(4-fluorophenyl)-*N*⁷-methylthiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1hba**)




56% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.50 (dd, J = 8.8, 5.6 Hz, 2H), 7.52 (ddd, J = 41.4, 34.8, 12.3 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.33 (dd, J = 11.7, 7.0 Hz, 3H), 7.11 (t, J = 8.7 Hz, 2H), 5.03 (s, 2H), 3.46 (dd, J = 8.4, 6.0 Hz, 2H), 3.34 (s, 3H), 1.75 (dt, J = 14.9, 7.5 Hz, 2H), 1.44 (dq, J = 14.8, 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.6, 168.4, 165.5, 163.5, 159.3, 157.6, 137.5, 133.4, 130.5, 130.5, 128.9, 127.7, 127.4, 115.2, 115.1, 98.6, 53.7, 45.7, 36.6, 36.6, 31.2, 20.1, 13.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{25}\text{FN}_5\text{S}^+$ 422.1809 Found 422.1807

*N*²,*N*⁷-Dibenzyl-5-(4-fluorophenyl)-*N*⁷-methylthiazolo[4,5-*d*]pyrimidine-2,7-diamine (**1hbb**)




38% yield as a white solid; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.06 (s, 1H), 8.43 – 8.34 (m, 2H), 7.43 – 7.31 (m, 6H), 7.31 – 7.22 (m, 6H), 4.98 (s, 2H), 4.64 (d, J = 5.3 Hz, 2H), 3.29 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 170.3, 164.4, 162.4, 158.8, 157.3, 138.4, 138.1, 134.7, 134.7, 129.8, 129.7, 128.6, 128.4, 127.4, 127.2, 127.1, 126.9, 115.1, 115.0, 99.0, 52.8, 47.1, 36.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{23}\text{FN}_5\text{S}^+$ 456.1653 Found 456.1656

N-Benzyl-5-(4-fluorophenyl)-*N*-methyl-2-(piperidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1hbe**)




66% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.55 – 8.49 (m, 2H), 7.37 – 7.26 (m, 5H), 7.11 – 7.02 (m, 2H), 5.01 (s, 2H), 3.66 (s, 4H), 3.31 (s, 3H), 1.70 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.4, 171.3, 165.2, 163.3, 160.4, 157.8, 138.1, 134.8, 134.7, 130.4, 130.3, 128.8, 127.5, 115.0, 114.8, 99.5, 53.6, 49.5, 36.4, 25.4, 24.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{25}\text{FN}_5\text{S}^+$ 434.1809 Found 434.1809

N-Benzyl-5-(4-fluorophenyl)-*N*-methyl-2-morpholinothiazolo[4,5-*d*]pyrimidin-7-amine (**1hbf**)



38% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.55 – 8.48 (m, 2H), 7.35 – 7.30 (m, 2H), 7.30 – 7.24 (m, 3H), 7.11 – 7.03 (m, 2H), 4.98 (s, 2H), 3.83 – 3.76 (m, 4H), 3.71 – 3.63 (m, 4H), 3.28 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.6, 170.8, 165.2, 163.2, 160.5, 157.9, 137.8, 134.5, 134.5, 130.3, 130.2, 128.8, 127.5, 127.3, 115.0, 114.8, 99.5, 66.1, 53.5, 48.2, 36.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{FN}_5\text{OS}^+$ 436.1602 Found 436.1601


N-Benzyl-5-(4-fluorophenyl)-*N*-methyl-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-amine (**1hbg**)



51% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.56 – 8.50 (m, 2H), 7.38 – 7.27 (m, 7H), 7.12 – 7.06 (m,


2H), 6.99 – 6.90 (m, 3H), 5.02 (s, 2H), 3.90 – 3.83 (m, 4H), 3.33 (s, 3H), 3.32 – 3.28 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.4, 171.0, 165.3, 163.3, 160.6, 158.0, 150.9, 137.9, 134.6, 134.6, 130.4, 130.3, 129.4, 128.8, 127.6, 127.4, 120.9, 117.0, 115.0, 114.9, 99.7, 53.6, 49.2, 48.1, 36.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{29}\text{H}_{28}\text{FN}_6\text{S}^+$ 511.2075 Found 511.2076

N-Butyl-5-(4-fluorophenyl)-7-morpholinothiazolo[4,5-*d*]pyrimidin-2-amine (**1hca**)




17% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.47 (dd, J = 8.4, 5.8 Hz, 2H), 7.09 (t, J = 8.6 Hz, 2H), 3.86 (s, 7H), 3.49 (t, J = 6.8 Hz, 2H), 1.79 (dt, J = 14.9, 7.4 Hz, 2H), 1.46 (dq, J = 14.7, 7.3 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, $\text{DMSO}-d_6$) δ 171.1, 162.4, 158.7, 157.1, 134.6, 129.8, 129.7, 115.2, 115.0, 99.7, 65.9, 45.7, 30.6, 19.5, 13.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{23}\text{FN}_5\text{OS}^+$ 388.1602 Found 388.1602

4-(5-(4-Fluorophenyl)-2-(piperidin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1hce**)





23% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.58 – 8.46 (m, 2H), 7.39 – 7.27 (m, 2H), 7.14 – 7.04 (m, 2H), 6.95 (ddd, J = 14.6, 8.0, 0.9 Hz, 3H), 3.87 (tdd, J = 8.0, 3.7, 1.8 Hz, 12H), 3.35 – 3.28 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.9, 170.9, 165.3, 160.4, 157.6, 134.6, 134.5, 130.3, 130.3, 115.0, 114.9, 100.6, 66.9, 49.7, 46.3, 25.4, 24.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{23}\text{FN}_5\text{OS}^+$ 400.1602 Found 400.1600



4-(5-(4-Fluorophenyl)-2-(4-phenylpiperazin-1-yl)thiazolo[4,5-*d*]pyrimidin-7-yl)morpholine (**1hcg**)







23% yield as a white solid; ^1H NMR (500 MHz, CDCl_3) δ 8.58 – 8.46 (m, 2H), 7.39 – 7.27 (m, 2H), 7.14 – 7.04 (m, 2H), 6.95 (ddd, J = 14.6, 8.0, 0.9 Hz, 3H), 3.87 (tdd, J = 8.0, 3.7, 1.8 Hz, 12H), 3.35 – 3.28 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 171.5, 171.0, 165.3, 163.4, 160.5, 157.7, 150.8, 134.4, 134.4, 130.3, 130.3, 129.4, 121.0, 117.0, 115.1, 114.9, 100.6, 66.8, 49.2, 48.2, 46.3. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{26}\text{FN}_6\text{OS}^+$ 477.1867 Found 477.1869



NMR spectra





















































































































































































































References

1. 4-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na⁺/K⁺-ATPase and Ras oncogene activity in cancer cells. *Eur. J. Med. Chem.*, 63 (2013), 213-223